Thomas Rutherford

Author PubWeight™ 47.18‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 2008 6.47
2 Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle 2009 3.60
3 Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A 2005 3.22
4 TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 2006 3.21
5 A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. Cancer Res 2010 2.15
6 Phenoxodiol--an isoflavone analog--induces apoptosis in chemoresistant ovarian cancer cells. Oncogene 2003 1.65
7 Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells. Cancer 2006 1.27
8 Interaction of the estrogen receptors with the Fas ligand promoter in human monocytes. J Immunol 2003 1.22
9 Resistance of ovarian carcinoma cells to docetaxel is XIAP dependent and reversible by phenoxodiol. Oncol Res 2004 1.20
10 Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer. J Oncol 2011 1.15
11 Macrophage migration inhibitory factor expression in ovarian cancer. Am J Obstet Gynecol 2007 1.09
12 Apoptosis-based evaluation of chemosensitivity in ovarian cancer patients. J Soc Gynecol Investig 2004 1.08
13 Long-term overweight and weight gain in early adulthood in association with risk of endometrial cancer. Int J Cancer 2011 1.03
14 Ezrin, a membrane-cytoskeletal linking protein, is highly expressed in atypical endometrial hyperplasia and uterine endometrioid adenocarcinoma. Cancer Lett 2002 1.03
15 Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma. Part I: morphologic features. Int J Surg Pathol 2004 1.02
16 Regulation of inflammation by the NF-κB pathway in ovarian cancer stem cells. Am J Reprod Immunol 2010 0.99
17 Cesarean scar ectopic pregnancy: case series and review of the literature. Am J Perinatol 2009 0.99
18 Differential regulation and function of the Fas/Fas ligand system in human trophoblast cells. Biol Reprod 2002 0.98
19 Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment. Cancer Med 2013 0.95
20 MyD88 predicts chemoresistance to paclitaxel in epithelial ovarian cancer. Yale J Biol Med 2006 0.93
21 Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) induces apoptosis in ovarian cancer cells. J Soc Gynecol Investig 2006 0.91
22 MicroRNA let-7a: a potential marker for selection of paclitaxel in ovarian cancer management. Gynecol Oncol 2011 0.90
23 Institutional review of primary non-hodgkin lymphoma of the female genital tract: a 33-year experience. Int J Gynecol Cancer 2014 0.88
24 Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2). Am J Obstet Gynecol 2013 0.88
25 Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol 2005 0.87
26 High frequency of putative ovarian cancer stem cells with CD44/CK19 coexpression is associated with decreased progression-free intervals in patients with recurrent epithelial ovarian cancer. Reprod Sci 2012 0.86
27 Regulation of Fas ligand expression by estrogen in normal ovary. J Soc Gynecol Investig 2002 0.84
28 Identification of differentially expressed genes in clinically distinct groups of serous ovarian carcinomas using cDNA microarray. Int J Mol Med 2004 0.83
29 Hormonal regulation of apoptosis and the Fas and Fas ligand system in human endometrial cells. Mol Hum Reprod 2002 0.82
30 HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor. Gynecol Oncol 2013 0.81
31 Phase I clinical trial of the mammalian target of rapamycin inhibitor everolimus in combination with oral topotecan for recurrent and advanced endometrial cancer. Int J Gynecol Cancer 2014 0.77
32 Adjuvant carboplatin, paclitaxel, and vaginal cuff brachytherapy for stage III endometrial cancer: analysis of outcomes and patterns of recurrence based on pathologic characteristics. Int J Gynecol Cancer 2015 0.76
33 HER-2/neu receptor gene status in endometrial carcinomas: a tissue microarray study. Histopathology 2010 0.76
34 Phase I study of perillyl alcohol in patients with refractory malignancies. Cancer Biol Ther 2002 0.76
35 Benign multicystic mesothelioma: a case report of three sisters. Rare Tumors 2009 0.75
36 Anti-tumor activity of phenoxodiol: from bench to clinic. Future Oncol 2008 0.75
37 Genotyping diagnosis of nongestational choriocarcinoma involving fallopian tube and broad ligament: a case study. Int J Gynecol Pathol 2014 0.75